Corporate and Regional Press Releases

Please find below a list of our press releases.

7 Mar 2017

BTG announces CE Mark Certification for DC Bead LUMI™, the first commer...

DC Bead LUMI™ provides real-time visible, lasting confirmation of bead location during and post-embolisation of hypervascular tumours in the liver

15 Feb 2017

BTG and Society of Interventional Oncology to explore role of minimally invas...

BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology

5 Dec 2016

PneumRx® Coils included in new global clinical guidelines and ...

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

5 Dec 2016

Le Canada, premier pays à bénéficier d’une nouvelle option de traitemen...

Les microsphères radio-opaques à élution médicamenteuse DC Bead LUMIMC offrent aux radiologistes interventionnels du Canada un traitement de nouvelle génération pour les patients atteints d’un cancer du foie

5 Dec 2016

Canada First to Receive New Treatment Option for Liver Cancer Patients

DC Bead LUMI™ Radiopaque Drug-Eluting Bead Offers Interventional Radiologists in Canada a Next Generation Treatment Option for Liver Cancer Patients

19 Oct 2016

First patient in Malaysia receives TheraSphere™ radioembolisation therapy

BTG plc (LSE: BTG), an international specialist healthcare company, today announced that the first patient in Malaysia was treated with TheraSphere™ – a transarterial radioembolisation (TARE) therapy, which targets primary liver cancer and metastatic colorectal cancer with a powerful dose of radiation while minimising exposure to healthy tissue.

14 Oct 2016

BTG and Mirada Medical announce CE Mark Certification for Simplicit90

BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit90Y™ dosimetry software, designed to optimise the planning of 90Y selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit90Y™ in Canada.

9 Sep 2016

BTG launches BETA™ Radiation Safety Programme, to reduce the risk of ra...

BTG plc (LSE: BTG), an international specialist healthcare company, today announced the launch of the BETA™ Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) with 90Y microspheres. Developed in collaboration with global experts, including Professor Jacob Kamen of the Mount Sinai Medical Center, the βETA™ Radiation Safety Programme analyses current practise and exposure risk, and provides recommendations to improve safety for healthcare professionals and patients.

23 Aug 2016

BTG receives Health Canada approval for DC Bead LUMI
...

BTG International Canada Inc., part of the global specialist healthcare company BTG (LSE:BTG), today announced that it has received approval from Health Canada for DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead that can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma (HCC) and malignant colorectal cancer metastasized to the liver (mCRC).

2 Aug 2016

BTG announces successful CE Mark reclassification for DC Bead® to Class I...

BTG plc (LSE: BTG), a global specialist healthcare company, today announced that it has obtained European Conformity (CE) Mark from the Notified Body British Standards Institution (BSI) following completion of the reclassification of DC Bead® and DC BeadM1TM as Class III medical devices under Rule 8 of Annex IX to Directive 93/42/EEC.